Corvus Pharmaceuticals, Inc. - Common Stock (CRVS)

This cloud-based payments provider delivers SaaS solutions to enterprise billers across utilities, finance, and healthcare sectors.

Corvus Pharmaceuticals develops immuno-oncology therapies, advancing clinical candidates for cancer and immune-related conditions.

Corvus (CRVS) Q4 2025 Earnings Call Transcript

Corvus increased its public stock offering to $175 million from $150 million, making 7.9 million shares of its common stock available for purchase at Wednesday’s closing price of $22.15.

The update follows the company’s release of cohort 4 data from its atopic dermatitis study of Soquelitinib.

Early eczema trial success and heavy trading are rapidly reshaping how investors view this drug developer, today, Jan. 20, 2026.

Corvus Pharmaceuticals reported a narrower Q2 2025 loss of $0.10 per share, beating estimates, with shares rising 5.8% after-hours. Positive Phase 1 data for soquelitinib in atopic dermatitis boosted investor optimism.

Corvus announced new interim data from its Phase 1 clinical trial evaluating Soquelitinib in patients with moderate to severe atopic dermatitis.

Corvus Pharmaceuticals, Inc.(NASDAQ:CRVS) on Thursday released new interim data from the Phase 1 clinical trial evaluating ...

Let's have a look at what is happening on the US markets before the opening bell on Friday. Below you can find the top gainers and losers in today's pre-market session.